4142:TPE
Adimmune Corp
16,15 TWD
arrow_downward
−0,62%(−0,10) 1 d
18 nov., 13:30:02 GMT+8 · TWD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för 4142 …
Öppen
16,35 TWD
Högt
16,55 TWD
Lågt
16,00 TWD
Börsvärde
6,94 md
Genomsn. vol.
1,09 mn
Volym
534,85 tn
52v högst
21,50 TWD
52v lägst
15,65 TWD
EPS
−0,34 TWD
Utestående aktier
235,29 mn
Antal anställda
564
Öppen
16,35 TWD
Högt
16,55 TWD
Lågt
16,00 TWD
Börsvärde
6,94 md
Genomsn. vol.
1,09 mn
Volym
534,85 tn
52v högst
21,50 TWD
52v lägst
15,65 TWD
EPS
−0,34 TWD
Utestående aktier
235,29 mn
Antal anställda
564
Nyheter och artiklar
Från webbkällor och nyhetspartner
The Motley Fool
·
för 17 minuter sedan
Vanguard S&P 500 ETF vs. Schwab U.S. Dividend ETF: How Much You’d Need to Collect $1,000 a Month From Each.
Benzinga
·
för 40 minuter sedan
Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead of FOMC Minutes— NVDA, AAOI, PANW in Focus
MarketWatch
·
för 1 timme sedan
The S&P 500 just broke a crucial support level. Here’s what history shows may happen now.
www.tokenpost.com
·
för 1 timme sedan
Nasdaq Gains 0.91% as S&P 500 Futures and Dow Also Advance
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Om Adimmune Corp